Utilisation des médicaments systémiques dans le traitement de la dermatite atopique modérée à sévère de l’adulte
-
Published:2024-06
Issue:5
Volume:4
Page:S22-S26
-
ISSN:2667-0623
-
Container-title:Annales de Dermatologie et de Vénéréologie - FMC
-
language:fr
-
Short-container-title:Annales de Dermatologie et de Vénéréologie - FMC
Reference13 articles.
1. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*;Wollenberg;Br J Dermatol,2021
2. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis;Simpson;N Engl J Med,2016
3. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis;Silverberg;N Engl J Med,2023
4. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials;Simpson;Br J Dermatol,2020
5. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial;Reich;The Lancet,2021